Lp(a): Addressing a Target for Cardiovascular Disease Prevention

Current Cardiology Reports
Nestor Vasquez, Parag H Joshi

Abstract

To review the current recommendations for lipoprotein(a) (Lp(a)) screening, the evidence behind the thresholds for increased cardiovascular disease (CVD) risk, and the available data supporting Lp(a) lowering. Lp(a) is almost entirely genetically determined and has an independent causal association with CVD. Measurement of Lp(a) is challenging given the structural heterogeneity of apolipoprotein a (apo(a)), for which isoform-insensitive immunoassays should be used. Current guidelines do not recommend treatment to lower Lp(a) but rather focus on intensified preventive measures including low-density lipoprotein cholesterol (LDL-C) lowering in patients with high Lp(a). Evidence suggests that levels higher than 50 mg/dL (125 nmol/L) identify significantly increased CVD risk. Mendelian randomization studies suggest that in order to have a clinically significant reduction in coronary heart disease, Lp(a) levels should be reduced by at least 60-70 mg/dL to attain a significant benefit. Ongoing studies of targeted therapy with antisense oligonucleotides (ASO) have shown promising reductions in Lp(a) up to 80%, but a cardiovascular outcomes trial is needed. There is unquestionably an increased risk for CVD in patients with elevated Lp(a...Continue Reading

References

Mar 1, 1991·The Journal of Clinical Investigation·T F ZioncheckR M Lawn
Mar 1, 1990·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·J LoscalzoA M Scanu
Jan 1, 1981·Atherosclerosis·G M KostnerG B Qunici
Mar 1, 1997·Journal of the American College of Cardiology·B F StewartC M Otto
Jan 1, 1963·Acta Pathologica Et Microbiologica Scandinavica·K BERG
Jun 11, 2009·JAMA : the Journal of the American Medical Association·Pia R KamstrupBørge G Nordestgaard
Jul 23, 2009·JAMA : the Journal of the American Medical Association·UNKNOWN Emerging Risk Factors CollaborationJohn Danesh
Dec 25, 2009·The New England Journal of Medicine·Robert ClarkeUNKNOWN PROCARDIS Consortium
Sep 16, 2010·Current Treatment Options in Cardiovascular Medicine·Parag H JoshiJoseph Miller
Oct 23, 2010·European Heart Journal·Børge G NordestgaardUNKNOWN European Atherosclerosis Society Consensus Panel
Nov 17, 2011·The New England Journal of Medicine·William E BodenWilliam Weintraub
Sep 25, 2012·Journal of Internal Medicine·F Kronenberg, G Utermann
Dec 4, 2012·Nature Genetics·Panos DeloukasNilesh J Samani
Feb 5, 2013·Journal of the American College of Cardiology·Pia R KamstrupBørge G Nordestgaard
Feb 8, 2013·The New England Journal of Medicine·George ThanassoulisUNKNOWN CHARGE Extracoronary Calcium Working Group
Oct 5, 2013·Arteriosclerosis, Thrombosis, and Vascular Biology·Paul J NestelDavid R Sullivan
Oct 29, 2013·Journal of the American College of Cardiology·Pia R KamstrupBørge G Nordestgaard
Nov 5, 2013·Mayo Clinic Proceedings·Terry A Jacobson
Jul 12, 2014·The New England Journal of Medicine·Martin J LandrayJane Armitage
Sep 12, 2015·Journal of the American College of Cardiology·Romain CapouladeSotirios Tsimikas
Dec 8, 2015·Journal of Lipid Research·Santica M Marcovina, John J Albers
Feb 21, 2016·Cardiovascular Drugs and Therapy·Florian Kronenberg
Aug 28, 2016·European Heart Journal·Alberico L CatapanoUNKNOWN ESC Scientific Document Group
Oct 30, 2016·The American Journal of Cardiology·Daniel GaudetFrederick J Raal
Nov 11, 2016·Circulation·Sang-Rok LeeSotirios Tsimikas
Feb 12, 2017·Journal of the American College of Cardiology·Sotirios Tsimikas
Jan 13, 2018·Journal of the American College of Cardiology·Sotirios TsimikasLijuan Liu
Feb 17, 2018·Circulation. Genomic and Precision Medicine·Sarah ParishUNKNOWN HPS2-THRIVE Collaborative Group
Jun 22, 2018·JAMA Cardiology·Stephen BurgessUNKNOWN European Prospective Investigation Into Cancer and Nutrition–Cardiovascular Disease (EPIC-CVD) Consortium
Jul 18, 2018·Journal of the American College of Cardiology·Nancy R CookPaul M Ridker
Dec 28, 2018·Circulation·Michelle L O'DonoghueMarc S Sabatine

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

© 2021 Meta ULC. All rights reserved